OVIDREL

(Choriogonadotropin alfa)

Phase 1Small molecule

OOrganon and Co

OVIDREL is one of 11 small molecule programs targeting Traumatic Brain Injury. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Traumatic Brain InjuryNot yet recruiting

Traumatic Brain InjuryPhase 1

Not yet recruiting

Competition

Competitive Landscape

12 competitors in Traumatic Brain Injury

#DrugCompanyPhaseTrials

Namenda

AbbVie

Phase 2

1 2

Hyperbaric Oxygen Therapy

PPaul G. Harch, M.D.

Phase 2

2 3

Allorx

TThe Foundation for Orthopaedics and Regenerative Medicine

Phase 1

1 4

Bont-a

SSir Run Run Shaw Hospital

Phase 2

1 5

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 6

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 7

Hyperpolarized Pyruvate

SSunnybrook Health Sciences Centre

Phase 1

1 8

OVIDREL

OOrganon and Co

Phase 1

1 9

Hyperpolarized [1-13c] Pyruvate

UUniversity of Texas Southwestern Medical Center

Phase 1

1 10

Sterile Saline

CClear Scientific, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1Not yet recruiting

Traumatic Brain Injury

NCT07557615

Clinical

Trials by Indication[1]

Embryo Transfer1 trial

Modified Luteal Support for Frozen-Thawed Embryo Transfer - A Prospective Study

Unknown status·SSheba Medical Center·Phase 4·NCT02825290·62 enrolled

Traumatic Brain Injury1 trial

Chorionic Gonadotropin to Improve Rehabilitation After Brain Injury - The COGNI-REHAB Study

Not yet recruiting·VVA Office of Research and Development·Phase 1·NCT07557615·50 enrolled

Regulatory

FDA Approval Timeline[4]

Oct 20, 1976

PREGNYL

BLA BLA017692

Sep 20, 2000

OVIDREL

BLA BLA021149

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Choriogonadotropin alfa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Choriogonadotropin alfa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Choriogonadotropin alfa. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA021149). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Organon and Co company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: OOrganon and Co

OVIDREL

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Embryo Transfer1 trial

Traumatic Brain Injury1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News